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In South Africa (SA), the risk of cerebrovascular disease is significant; 
it is estimated that approximately 240 strokes occur daily.[1] 
Worldwide, up to 3 million people per year suffer atrial fibrillation 
(AF)-related strokes.[2] SA patients with irreversible AF currently use 
warfarin as first-line treatment. Dabigatran (Pradaxa; Boehringer 
Ingelheim) is an oral anticoagulant with direct thrombin inhibitory 
action and was registered in SA in September 2012 for the prevention 
of cardioembolic stroke in patients with non-valvular AF.
The Randomized Evaluation of Long-term Anticoagulation 
Therapy (RE-LY)[3] trial was a non-inferiority trial with 2-year 
follow-up, comparing the use of dabigatran with warfarin in patients 
with AF who were at risk of stroke. A total of 18 113 people in 44 
countries were enrolled and randomised into three treatment arms, 
two blinded dabigatran arms, using two fixed doses of dabigatran 
(110 mg twice daily and 150 mg twice daily), and a blinded, adjusted-
dose warfarin arm. The primary study outcome was prevention of 
stroke or systemic embolism. The primary safety outcome was major 
haemorrhage. Secondary outcomes were stroke, systemic embolism 
and death rates.
Both dabigatran doses were non-inferior to warfarin in respect 
of the primary efficacy outcome. In addition, the 150 mg dose of 
dabigatran was superior to warfarin with respect to prevention of 
stroke or systemic embolism, and the 110 mg dose was superior 
to warfarin in respect of major bleeding. The RE-LY trial showed 
relative reductions of 9.5% and 34.3% in the risk of stroke or systemic 
embolism for twice-daily dabigatran 110 mg and 150 mg, respectively, 
compared with warfarin. All-cause mortality was reduced by 9.2% 
and 12% for the 110 mg and 150 mg doses of dabigatran, respectively, 
compared with warfarin.[3]
Internationally, economic appraisals were performed to evaluate 
the use of dabigatran for patients with AF. In an economic study in 
the USA, the estimated cost per quality-adjusted life year (QALY) 
gained proved cost-effective below a willingness-to-pay threshold of 
US$50 000 per QALY when comparing dabigatran 150 mg twice daily 
with warfarin. The cost-effectiveness (CE) was, however, dependent 
on the pricing of dabigatran in the USA.[4] Economic appraisals 
performed in the UK had similar results.[5]
In SA, the daily cost of dabigatran is significantly more than the 
cost of warfarin. Policy makers therefore need to understand the 
potential economic benefits that might be derived from the use of 
dabigatran compared with warfarin. Economic appraisals not only 
provide insight into the economic viability of substituting dabigatran 
for warfarin, but also assist in policy decision making. The objective 
of this study was to estimate the CE and budgetary impact of using 
dabigatran for stroke prevention in patients with AF in the SA private 
healthcare sector, thereby assisting in guiding policy.
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Background. Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered in South Africa (SA) to reduce the risk of 
stroke and systemic embolism in patients with atrial fibrillation (AF). Owing to the price disparity between warfarin (the current gold 
standard for treatment of patients with AF) and dabigatran, we conducted an economic appraisal of the use of dabigatran compared with 
warfarin from a payer perspective in the South African private healthcare setting.
Objectives. To estimate the cost-effectiveness (CE) and budget impact of dabigatran compared with warfarin for the prevention of stroke 
in AF patients.
Methods. A previously published Markov model was populated with SA cost and mortality data to estimate the CE and budget impact 
analysis of dabigatran over a lifetime horizon. The model population consisted of a cohort of patients of whom those aged younger than 80 
years used dabigatran 150 mg twice daily and those older than 80 years 110 mg twice daily. Modelled outcomes included total cost, quality-
adjusted life years (QALYs) and incremental CE ratio (ICER), with the effectiveness measured by QALYs gained.
Results. Dabigatran compared with warfarin as first-line treatment was estimated to have an ICER of R93 290 and an average incremental 
cost per beneficiary per month of R0.39 over a 5-year period. Conservative assumptions were made regarding the number of international 
normalised ratio monitoring tests for patients on warfarin, and the ICER is estimated to decrease by as much as 15.7% under less stringent 
assumptions. A robust sensitivity analysis was also performed.
Conclusion. Dabigatran as first-line treatment compared with warfarin for the use of stroke prevention in patients with AF is deemed cost-
effective when used in accordance with its registered indication in the SA private sector.
S Afr Med J 2013;103(4):241-245. DOI:10.7196/SAMJ.6471
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Methods
Kansal et al.[5] designed a CE model based on the outcome of the 
RE-LY trial in 2010. The CE model simulates disease progression and 
estimates quality of life and incremental cost per QALY for patients 
with AF in SA.
The CE results were estimated using the sequential dose model 
setup, which ensures that patients aged <80 years receive 150 mg 
dabigatran twice daily and patients >80 years 110 mg twice daily. 
Warfarin-related outcomes from the RE-LY trial are referred to as 
trial-like warfarin in the CE model, and in the model base case we 
used this parameter for warfarin utilisation in patients with AF. The 
‘real-world’ utilisation of warfarin in patients with AF, incorporating 
less stringent international normalised ratio (INR) testing and 
sensitivity, was investigated by comparing dabigatran with real-world 
warfarin as first-line treatment.
The CE model developed by Kansal et al.[5] was made available for 
adaptation to the SA private healthcare setting and populated with 
SA mortality and cost data. These are discussed under ‘Inputs and 
assumptions’ below.
A budget impact analysis (BIA) module was developed by the 
authors. The BIA module considers and compares a status quo 
scenario where only warfarin is used for stroke prevention in AF 
patients, and a new intervention scenario in which some of the AF 
patients receive dabigatran for stroke prevention. The BIA module 
is a dynamic model that incorporates the prevalence, incidence and 
mortality of AF patients in SA. The budget impact is estimated over 
5 years and is expressed as the incremental cost per beneficiary per 
month (ICPBPM).
The CE model and BIA model results were estimated using the base-
case scenario parameters as set out in Table 1. Table 1 also indicates the 
rationale for using these parameters as a base-case scenario.
Event costs used to populate the model were estimated using 
2007 medical scheme claims data. The data included 2.1 million 
claim lines occurring between January 2000 and May 2007. The 
claims represent all patients who had a claim with a diagnosis code 
contained in chapter IX of the 10th revision of the International 
Statistical Classification of Diseases and Related Health Problems (ICD 
10) coding system. These claims were adjusted to 2011 values using 
medical inflation figures as published by Statistics South Africa.[6]
Event costs are defined as: (i) the costs of clinical events that 
are associated with a patient with AF, notably stroke, systemic 
embolism (SE) and transient ischaemic attack (TIA); and (ii) the 
costs of adverse events in patients on treatment for AF related to 
bleeding tendencies.
Event costs were estimated separately for patients who were 
physically independent (i.e. able to function independently of 
assistance from a caretaker or family member) after any event, 
patients who were only moderately physically dependent, and 
patients who were totally physically dependent. The model accounts 




There are no publicly available life tables for the SA medically insured 
population. The SA85-90 life tables published by the Actuarial 
Society of South Africa[7] were used as an approximation for the 
mortality experience of the SA private sector. The mortality rate of 
the SA85-90 population is greater than the mortality rates used by 
Kansal et al.,[5] with the difference more pronounced in females than 
in males.
Drug costs
The cost of dabigatran was supplied by Boehringer Ingelheim SA (BI 
SA). It is assumed that patients with an INR of <2 will require 5 mg of 
warfarin per day, those with an INR within the range of 2 - 3, 3 mg of 
warfarin per day, and those with an INR of >3, 1 mg of warfarin per 
day. The costs of these drugs are set out in Table 2.
Event costs
The cost of ischaemic stroke (IS) was estimated by calculating the 
total claimed amount for any hospitalisation during which a patient 
had a claim reflecting stroke, not specified as haemorrhage or 
infarction. It was assumed that the median cost of the first quarter of 
the data is the average cost for a patient who is independent following 
an IS. Similarly, it was assumed that the cost for a patient who is 
moderately disabled following an IS is represented by the median 
cost of the second quarter of the sorted data, the cost of a fatal IS by 
the median of the third quarter of the data, and the cost for a patient 
who is totally dependent after an IS by the median of the last quarter 
of the data. Owing to a lack of robust data, it was assumed that 
intracranial haemorrhage (ICH), haemorrhagic stroke (HS) and IS 
all incurred the same cost. SE was estimated by calculating the total 
claimed cost in hospital, where at least one claim with pulmonary 
embolism occurred. The cost of fatal cases was estimated using the 
first quartile of the systemic event costs, and the non-fatal cases were 
estimated using the third quartile of the costs. A TIA was estimated 
as the median total hospital cost where at least one claim with TIA 
Table 1. Base-case scenario parameters
Parameter Input used Rationale
Single-dose/sequential dose model Sequential dose model Dabigatran registered indication
Patient population <80 RE-LY population This allows patients to have a dose reduction when they reach 
age 80 years
Dabigatran indication in treatment sequence 1st line Dabigatran registered indication
1st-line treatment comparator Trial-like warfarin High data quality
2nd-line treatment when dabigatran is 1st line No treatment Most conservative option
INR adjustment Weighted warfarin approach Calculates the percentage of patients with INR in and out of 
range and applies a risk adjustment to each category 
Time horizon Lifetime Standard practice in CE modelling 
INR = international normalised ratio; CE = cost-effectiveness.
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occurred. The cost of acute myocardial infarction (MI) was estimated 
as the median total cost in hospital where at least one claim with acute 
MI occurred, and it was assumed that fatal and non-fatal MIs have 
the same cost. Fatal extracranial haemorrhage (ECH) and non-fatal 
gastrointestinal (GI) bleeds were estimated from the total cost of 
hospital stay claims. It was assumed that discontinuation of treatment 
after an event, treatment switch and death from unrelated causes are 
not associated with additional costs. The event costs are summarised 
in Table 2.
A patient’s follow-up costs subsequent to a stroke were estimated 
from costs incurred after the patient had been discharged from 
hospital. A zero cost was assumed when a patient was independent 
without a stroke history. It was assumed that treatment discontinuation 
without an event would result in the cost of one consultation. These 
costs are also summarised in Table 2.
Treatment uptake
The BIA module compares a cohort of AF patients using warfarin 
with the same cohort should they initiate treatment with dabigatran. 
The BIA module is based on the assumption that 3 333 AF patients 
will receive dabigatran for stroke prevention in year 1 (which 
comprised 20% of the total number of AF patients). Furthermore, it 
was assumed that the total number of patients receiving dabigatran 
will increase by 10% per annum. These assumptions are based on 
market growth projections provided by BI SA. 
Warfarin monitoring costs
The INR monitoring cost of patients treated with warfarin is 
incorporated into the model. The costs for one INR test and one 
specialist consultation are shown in Table 2. Owing to lack of SA data, 
the INR testing frequency was estimated using medical schemes’ 
claims data and verified by consultation with two key opinion leaders 
(KOLs). The claims data are shown in Fig. 1 and suggest a bimodal 
distribution, indicating that a large proportion of patients receive 
an INR test twice a month or more frequently, and another large 
proportion monthly. These two centroids are assumed to represent 
the average number of tests for uncontrolled and controlled patients. 
The KOLs agreed that controlled patients will have monthly INR 
tests, while the frequency of INR tests for uncontrolled patients can 
vary between daily and bimonthly.
Accordingly, for the base case, it was estimated that patients with 
an INR within the range of 2 - 3 would have an average of 12 INR tests 
per annum, while patients with an INR outside this range would have 
24. These are thought to be conservative estimates, as many patients 
receive more than two INR tests per month (Fig. 1). It was assumed 
that patients with an INR within and outside the range of 2 - 3 will 
have three and six specialist consultations per year, respectively.
Results
Table 3 sets out the CE results for the base-case scenario with 
effectiveness measured by QALYs gained. Table 4 shows the BIA results.
Sensitivity analysis
The base-case scenario compared using dabigatran as first-line 
treatment with trial-like warfarin, with no treatment as second-line 
treatment.
The choice of comparator when dabigatran was used as a first-
line option was altered between trial-like warfarin and real-world 
warfarin. The ICER decreases to R90 077 (-3.45%) and the ICPBPM 
decreases by 3.26% on average over a period of 5 years.
Sensitivity analysis was performed on INR monitoring. For the 
scenario in which a patient’s INR falls outside the range, one of the 
KOLs advised that ‘If on long-term warfarin, as many as 36 tests per 
year might be performed.’ Sensitivity analysis on the number of INR 
tests for uncontrolled patients was therefore conducted and the ICER 
was estimated with 24 and 36 INR tests annually. The number of INR 
Table 2. Model inputs
Drug cost per day (R)
Dabigatran 110 mg bid 24.66
Dabigatran 150 mg bid 24.66
Warfarin INR <2 1.65
Warfarin INR 2 - 3 1.06
Warfarin INR >3 0.94
Event, n
Fatal IS 39 353
IS, independent 10 056
IS, moderate disability 17 000
IS, totally dependent 75 865
SE, fatal 18 040
SE, non-fatal 72 472
TIA 15 900
ICH, fatal 39 353
ICH, independent 10 056
ICH, moderate disability 17 000
ICH, totally dependent 75 865
HS, fatal 39 353
HS, independent 10 056
HS, moderate disability 17 000
HS, totally dependent 75 865
ECH (non-brain), fatal 47 088
ECH (non-brain), non-fatal, non-GI 3 310
ECH (non-brain), non-fatal, GI 12 317
Minor bleed 3 310
Acute MI, fatal 78 869
Acute MI, non-fatal 78 869
Discontinuation of treatment following an event 0
Treatment switch 0
Death from unrelated causes 0
Follow-up costs per year (R)
Follow-up – independent with stroke history 19 490
Moderate disability with stroke history 23 120
Dependent disability with stroke history 61 370
Treatment discontinuation without an event 378
Monitoring costs per test (R)
INR monitoring 104.80
Specialist consultation 378.38
INR = international normalised ratio; IS = ischaemic stroke; SE = systemic embolism; 
TIA = transient ischaemic attack; ICH = intracranial haemorrhage; HS = haemorrhagic 
stroke; ECH = extracranial haemorrhage; GI = gastrointestinal; MI = myocardial infarction.
RESEARCH
244  April 2013, Vol. 103, No. 4  SAMJ
tests conducted, and the estimated ICER for uncontrolled patients 
per year, are shown in Fig. 2. The number of tests for a controlled 
patient was not altered from the base case. The ICER decreases 
by as much as 15.7% when increasing the number of INR tests for 
uncontrolled warfarin patients from 24 tests per annum to 36 tests 
per annum.
The BIA results for an uncontrolled warfarin patient, assuming 
that these patients receive 30 and 36 INR tests per year, indicate that 
the ICPBPM ranges between R0.14 and R0.60 for 30 INR tests and 
between R0.13 and R0.56 for 36 tests. The relative reductions from 
the base case are 4.7% and 9.4% in the first year for 30 and 36 INR 
tests, respectively. The average decreases of the ICPBPM over 5 years 
are 5.2% and 10.5%, respectively.
In the opinion of the KOLs, a stable individual can use up to 20 mg 
of warfarin a day; sensitivity analysis was therefore also performed on 
the amount of warfarin used by a patient within the INR range 2 - 3 
and that for a patient whose INR is <2. The amount was adjusted to 


















Fig. 2. Incremental cost-effectiveness ratio when the number of international 
normalised ratio tests for an uncontrolled patient on warfarin increases.
Table 3. Base-case cost-effectiveness results
Treatment option Drug costs (R) Event costs (R) Follow-up costs (R) Total cost (R) LYs QALYs ICER (R)
Dabigatran 60 365 23 426 236 496 320 286 9.33 7.19 93 290
Trial-like warfarin 24 243 24 888 252 119 301 249 9.14 6.98
LYs = life years; QALYs = quality-adjusted life years; ICER = incremental cost-effectiveness ratio.
Table 4. Base-case budget impact analysis results over a 5-year period
Year
Total cost (R)
Incremental cost (R) ICPBPM (R)Before dabigatran launch After dabigatran launch
2012 354 331 177 369 022 581 14 691 404 0.15
2013 720 191 835 747 948 446 27 756 611 0.28
2014 1 095 201 218 1 135 134 295 39 933 077 0.40
2015 1 476 730 304 1 528 308 981 51 578 677 0.52
2016 1 861 716 479 1 924 686 994 62 970 514 0.63
ICPBPM = incremental cost per beneficiary per month.





































































Fig. 1. Frequency of prothrombin tests for patients on warfarin estimated from medical scheme data. The red line indicates a smoothed kernel estimate for the 
distribution of international normalised ratio test frequency.
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20 mg a day from 3 mg for a patient within range and from 5 mg for 
a patient with an INR <2. For a patient with an INR >3, warfarin use 
remained at 1 mg a day. The ICER decreases to R27 055, representing 
a 71% reduction from the base-case results. The estimated BIA results 
reveal an average decrease of 48% over a period of 5 years, ranging 
from R0.08 in year 1 to R0.32 in year 5.
Discussion
In this study, we first estimated the CE of dabigatran as first-line 
treatment compared with warfarin, followed by no second-line 
treatment. Secondly, the budgetary impact of introducing dabigatran 
into the SA private healthcare market over a 5-year period was 
investigated. CE was demonstrated for patients using 150 mg of 
dabigatran twice daily if aged <80 years, after which they will switch 
to 110 mg dabigatran twice daily. The analysis estimated the total 
cost for dabigatran and warfarin, as well as the life years and QALYs 
for both treatment arms, to calculate the ICER with effectiveness 
measured by QALYs gained.
At an ICER of R93 290, dabigatran proves cost-effective when 
compared with trial-like warfarin as a first-line treatment in patients 
with AF and at risk of suffering IS. The budgetary impact was 
estimated as R0.15 per beneficiary per month in the first year, 
increasing to R0.63 in the 5th year. Although this appears to be small, 
it should be considered by policy makers and healthcare funders as 
part of their total budget, the burden of disease of their respective 
risk pools and the potential opportunity cost of funding dabigatran 
in the future.
The authors considered various clinical scenarios (through 
sensitivity analyses) to estimate the CE and budgetary impact of 
treating AF patients with dabigatran as first-line therapy for stroke 
prevention.
It was observed that the results are not very sensitive to the 
comparator in first-line treatment when using trial-like or real-world 
warfarin. The base-case results are considered to be conservative, 
since the cost offset by avoidance of INR testing through the use of 
dabigatran reduces the ICER by up to 15.7% under less conservative 
assumptions. The base-case scenario is also sensitive to an increase in 
the amount of warfarin used by a patient according to the INR range.
Comparing the model inputs used by Kansal et al.,[5] and the inputs 
used to populate the model for the SA private sector, the largest 
relative cost difference was shown for a patient being independent, 
moderately disabled and totally dependent as a result of IS, IH and 
HS. The mortality rates used by Kansal et al. were lower than the 
mortality rates used for the SA health sector. Mortality rates in SA are 
on average 23% and 27% higher for males and females, respectively, 
than those in the UK model. This together with the cost differences 
influenced the results generated for the SA population.
The National Institute for Health and Clinical Excellence (NICE) 
technology appraisal guidance[8] showed that the INR monitoring 
costs for the population on warfarin are difficult to quantify 
accurately. This is due to the variation in the costs of INR testing in 
the UK, as well as uncertainty about the frequency of INR testing, 
which is dependent on the patient’s INR range. NICE made a key 
recommendation that dabigatran be recommended as a treatment 
option for the prevention of strokes in patients with AF, within the 
licensed indications of use. Furthermore, NICE agreed that a dose of 
150 mg was clinically more effective in the RE-LY trial.
We conclude that dabigatran should be considered as a cost-
effective option within its registered indication when compared 
with warfarin. Accurate data on the resource utilisation (specifically 
frequency of INR testing) associated with stroke prevention in AF 
will enhance the robustness of the results. Dabigatran is worthy of 
consideration as a treatment option when managing patients with 
AF, as it is the only treatment that, when compared with warfarin, 
provides a superior reduction in IS and HS, which is the main goal of 
anticoagulation treatment.
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